Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab.

Hematol Oncol Stem Cell Ther

Taussig Cancer Institute of the Cleveland Clinic, Maroone Cancer Center, Cleveland Clinic-Florida, Weston, FL, USA. Electronic address:

Published: June 2016

Thrombotic thrombocytopenic purpura (TTP) is a multisystem disorder characterized by microvascular aggregation of platelets and fibrin strands causing thrombocytopenia, microangiopathic hemolytic anemia, and organ dysfunction. TTP can develop as a result of a deficiency in ADAMTS13 enzyme activity due to either a genetic defect or, more commonly, the development of anti-ADAMTS13 autoantibodies. TTP can also be associated with pregnancy, organ transplant, lupus, infections, and drugs. Here, we present a case of TTP that developed shortly after the start of clopidogrel treatment for acute ischemic stroke and acute myocardial infarction, and describe the clinical presentation, refractory course of the disease, and successful induction of remission through the use of rituximab in a setting of pre-existing autoimmune diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hemonc.2015.11.003DOI Listing

Publication Analysis

Top Keywords

thrombotic thrombocytopenic
8
thrombocytopenic purpura
8
clopidogrel-induced refractory
4
refractory thrombotic
4
purpura treated
4
treated rituximab
4
rituximab thrombotic
4
ttp
4
purpura ttp
4
ttp multisystem
4

Similar Publications

Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially life-threatening complication whose association with COVID-19 is controversial. Understanding this connection is essential due to its significant impact on patient outcomes, and timely diagnosis and intervention are critical in managing this condition effectively.

Areas Covered: This paper presents a case of TTP triggered by COVID-19 infection in a 48-year-old female.

View Article and Find Full Text PDF

UV immunothrombotic trombocytopenic purpura.

Transfus Apher Sci

January 2025

Banco de Sangre y Tejidos de Navarra, Navarre Health Service (SNS-O), Pamplona, Spain; Grupo Español de Aféresis (GEA)(Spanish Group of Apheresis), Spain. Electronic address:

View Article and Find Full Text PDF

Congenital thrombotic thrombocytopenic purpura (cTTP) is a thrombotic microangiopathy (TMA) characterized by severe hereditary ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs 13) deficiency caused by mutations. This rare autosomal recessive genetic disorder is often misdiagnosed as immune thrombocytopenia (ITP) or hemolytic uremic syndrome (HUS). Here, we report a 21-year-old male cTTP patient with a compound heterozygous mutation.

View Article and Find Full Text PDF

A 35-year-old male with a history of hypertension presented with a thunderclap headache. Laboratory tests revealed isolated mild thrombocytopenia and plain brain imaging was normal. Subsequently he developed chest pain and breathlessness, accompanied with an acute kidney injury, elevated troponins and worsening thrombocytopenia.

View Article and Find Full Text PDF

[Not Available].

Tidsskr Nor Laegeforen

January 2025

Medisinsk avdeling, Drammen Sykehus.

Background: When haemolytic anaemia, thrombocytopenia and renal failure are present, a thrombotic microangiopathic (TMA) condition should be suspected. We describe the various differential diagnoses of primary TMA syndromes, their clinical findings, clinical workup and treatment.

Case Presentation: A previously healthy man in his fifties was hospitalised with anaemia, thrombocytopenia, bilirubinaemia and acute renal failure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!